Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis

References

• Sipe J D. Amyloidosis. Crit Rev Clin Lab Sci 1994; 31: 325–354
   PubMed Web of Science ®Google Scholar
• Benson M D. Amyloidosis. The metabolic and molecular bases of inherited disease. 8th ed, A L Beaudet, W S Sly, D Valle. McGraw-Hill, New York 2001; 5345–5378
   Google Scholar
• Skinner M, Shirahama T, Benson M D, Cohen A S. Murine amyloid protein AA in casein induced experimental amyloidosis. Lab Invest 1977; 36: 420–427
   PubMed Web of Science ®Google Scholar
• Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation into amyloid fibrils in vivo. Scand J Immunol 1985; 21: 282–287
   Web of Science ®Google Scholar
• Tape C, Tan R, Nesheim M, Kisilevsky R. Direct evidence for circulating apo-SAA as the precursor of tissue AA amyloid deposits. Scand J Immunol 1988; 28: 317–324
   PubMed Web of Science ®Google Scholar
• Husby G, Marhaug G, Dowton B, Sletten K, Sipe J D. Serum amyloid A (SAA): biochemistry genetics and the pathogenesis of AA amyloidosis. Amyloid: Int J Exp Clin Invest 1994; 1: 119–137
   Web of Science ®Google Scholar
• Kisilevsky R, Young I D. Pathogenesis of amyloidosis. Bailliere's clinical rheumatology: reactive amyloidosis and the acute-phase response, G Husby. Bailliere Tindall, London 1994; 8: 613–626, No. 3
   Google Scholar
• Axelrad M A, Kisilevsky R, Willmer J, Chen S J, Skinner M. Further characterizations of amyloid-enhancing factor. Lab Invest 1982; 47: 139–146
   PubMed Web of Science ®Google Scholar
• Johan K, Westermark G T, Engström U, Gustavsson A, Hultman P, Westermark P. Acceleration of AA-amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci USA 1998; 95: 2558–2563
   PubMed Web of Science ®Google Scholar
• Rochet J C, Lansbury P T. Amyloid fibrillogenesis: Themes and variations. Curr Opin Struct Biol 2000; 10: 60–68
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss D T, Schell M, Hrncic R, Murphy C L, Wall J, McGavin M D, Pan H J, Kabalka G W, Paulus M J. Transgenic mouse model of AA amyloidosis. Am J Pathol 1999; 154: 1267–1272
   PubMed Web of Science ®Google Scholar
• Paulus M J, Sari-Sarraf H, Gleason S S, Bobrek M, Hicks J S, Johnson D B, Behel J K, Thompson L H, Allen W C. A new X-ray computed tomography system for laboratory mouse imaging. IEEE Trans Nucl Sci 1999; 46: 558–564
   Web of Science ®Google Scholar
• Paulus M J, Gleason S S, Kennel S J, Hunsicker P R, Johnson D K. High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia 2000; 2: 62–70
   PubMed Web of Science ®Google Scholar
• Hawkins P N, Myers M J, Lavender J P, Pepys M B. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988; 1: 1413–1418
   PubMed Web of Science ®Google Scholar
• Hawkins P N, Myers M J, Epenetos A A, Caspi D, Pepys M B. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med 1988; 167: 903–913
   PubMed Web of Science ®Google Scholar
• Hawkins P N, Lavender J P, Pepys M B. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323: 508–513
   PubMed Web of Science ®Google Scholar
• Hawkins P N. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11: 649–655
   PubMed Web of Science ®Google Scholar
• Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1991; 89: 232–235
   Web of Science ®Google Scholar
• Kovalchuk A L, Kim J S, Park S S, Coleman A E, Ward J M, Morse H C, III, Kishimoto T, Potter M, Janz S. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 2002; 99: 1509–1514
   PubMed Web of Science ®Google Scholar
• McConahey P J, Dixon F J. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol 1996; 29: 185–189
   Google Scholar
• Kennel S J, Lankford T K, Foote L J, Shinpock S G, Stringer C. CD44 expression on murine tissues. J Cell Sci 1993; 104(Pt 2)373–382
   PubMed Web of Science ®Google Scholar
• Gregor J, Gleason S, Kennel S J, Paulus M, Benson T, Wall J. Approximate volumetric system models for microSPECT. Proceedings of the IEEE Medical Imaging Conference. RomeItaly October, 2004
   Google Scholar
• Gregor J, Gleason S, Paulus M, Cates J. Fast Feldkamp reconstruction based on focus of attention and distributed computing. Int J Imaging Sys Tech 2002; 12: 229–234
   Web of Science ®Google Scholar
• Kennel S J, Lankford T, Hughes B, Hotchkiss J A. Quantitation of a murine lung endothelial cell protein, P112, with a double monoclonal antibody assay. Lab Invest 1988; 59: 692–701
   PubMed Web of Science ®Google Scholar
• Akabani G, Kennel S J, Zalutsky M R. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. J Nucl Med 2003; 44: 792–805
   PubMed Web of Science ®Google Scholar
• Murphy C L, Eulitz M, Hrncic R, Sletten K, Westermark P, Williams T, Macy S D, Wooliver C, Wall J, Weiss D T, Solomon A. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001; 116: 135–142
   PubMed Web of Science ®Google Scholar
• Jager P L, Hazenberg B P, Franssen E J, Limburg P C, van Rijswijk M H, Piers D A. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 1998; 39: 699–706
   PubMed Web of Science ®Google Scholar
• Hachulla E, Maulin L, Deveaux M, Facon T, Blétry O, Vanhille Ph, Wechsler B, Godeau P, Levesque H, Hatron P Y, et al. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: From diagnosis to prognosis. Am J Med 1996; 101: 77–87
   PubMed Web of Science ®Google Scholar
• Pepys M B, Booth, Dr, Hutchinson W L, Gallimore J R, Collins P M, Hohenester E. Amyloid P component. A critical review. Amyloid: Int J Exp Clin Invest 1997; 4: 274–295
   Web of Science ®Google Scholar
• Hawkins P N, Wootton R, Pepys M B. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990; 86: 1862–1869
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Lemieux L J, Fraser P E, Kong X, Hultin P G, Szarek W A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. Nat Med 1995; 1: 143
   PubMed Web of Science ®Google Scholar
• Pepys M B, Herbert J, Hutchinson W L, Tennent G A, Lachmann H J, Gallimore J R, Lovat L B, Bartfai T, Alanine A, Hertel C, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254–259
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss D T, Wall J S. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Can Biother Radiopharm 2003; 12: 853–859
   Google Scholar